Clinical trial · Observational
Observational Study to Assess Adherence Oral Anticancer Therapies
Observational Study to Assess Adherence of Oral Anticancer Therapies
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Oral anticancer treatments are increasingly numerous. They represent an additional alternative in the therapeutic arsenal of the clinician, and appear to satisfy patients who prefer this route of administration over intravenous treatment. The objective of oral therapies is twofold: to remove the constraints and risks associated with infusions and to allow the patient to follow his treatment at home. However, they have significant adverse effects that may affect patients, who are sometimes at a disadvantage compared to how they are treated, and potentially lead to non-compliance with the consequences. This study will identify the factors associated with non-adherence and determine the impact of this non-adherence in terms of treatment efficacy and tolerance. The aim of this routine care study is to evaluate the adherence to oral anticancer therapies during 3 months.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Adherence, Patient | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Drug diary filling | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Compliance with treatment
- timeFrame
- 3 months
- description
- Treatment adherence will be assessed by the number of treatment units taken in relation to the prescribed amount. A patient will be considered as observing if he has received at least 80% of the dose initially prescribed.
Secondary outcomes (2)
- measure
- Toxicity
- timeFrame
- 3 months
- description
- The toxicity of the treatment will be assessed and graded, at each medical consultation, according to the classification NCI-CTCAE V4.03, in observing and non-observing patients.
- measure
- Response to treatment
- timeFrame
- 3 months
- description
- Treatment response will be assessed according to clinical status and radiological criteria RECIST 1.1.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age\> 18 years * Cancer proved histologically. * Patient receiving an initial prescription for oral anticancer therapy, excluding hormone therapy * Illness measurable or assessable by imaging * Patient affiliated to a social security scheme * Patient having been informed of the study * Non-opposition of the patient Exclusion Criteria: * Contraindication to oral treatment * Patient's refusal * Patient under tutelage, curatorship or safeguard of justice * Psychiatric illness and / or condition of the patient compromising understanding of information or conduct of the study
References
Publications (0)
Data not yet available